BrainStorm Cell Therapeutics (BCLI)

Executive Summary

BrainStorm Cell Therapeutics is a publicly traded clinical-stage biotechnology company focused on developing autologous cellular therapies for neurodegenerative diseases, primarily amyotrophic lateral sclerosis (ALS). Its lead product, NurOwn (debamestrocel), is an MSC-NTF cell therapy designed to deliver neurotrophic factors and immunomodulatory signals to the central nervous system. The company recently reached a Special Protocol Assessment (SPA) agreement with the FDA for a Phase 3b trial in ALS, which is now recruiting, and has presented biomarker data suggesting that longer-term treatment may benefit patients. With a market capitalization of approximately $7.7M, BrainStorm operates in a high-risk, high-reward space, given the historical challenges of ALS drug development and the company's prior Phase 3 trial that missed its primary endpoint.

Upcoming Catalysts (preview)

• Q2 2027Phase 3b trial interim analysis or enrollment milestone35% success
• Q4 2026FDA feedback on NurOwn regulatory pathway following SPA60% success
• Q3 2026Publication of additional biomarker data from long-term treatment50% success